|
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients Clinical research trials and The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients. The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients clinical trial. Participants frequently get the best healthcare available for their The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients  The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
For Condition: Cytomegalovirus Infections,HIV Infections
Status: No longer recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To evaluate the safety and efficacy of adefovir dipivoxil in prolonging survival of patients with advanced HIV disease. In CMV prophylaxis substudy: To evaluate the efficacy of adefovir dipivoxil in preventing the development of CMV end-organ disease in patients with advanced HIV coinfected with CMV. The optimal treatment for HIV infection and the prevention of CMV disease has not been identified. Currently available antiretroviral therapies are hampered by both significant toxicities and the development of resistance. In addition, agents for preventing CMV disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased compliance secondary to toxicities. Moreover, discordant results have been reported regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need for newer agents with anti-HIV and anti-herpesvirus activity that have good pharmacokinetic and safety profiles and that will be well tolerated by patients. Adefovir dipivoxil is an oral pro-drug of PMEA, a nucleoside analog with activity against a broad spectrum of retroviruses and herpesviruses, including important human pathogens, such as HIV-1, HIV-2 and CMV. Due to its anti-HIV and anti-herpesvirus activity, adefovir dipivoxil may be able to decrease the incidence of opportunistic herpesvirus infections and prolong survival in patients with advanced HIV infection.
Details: The optimal treatment for HIV infection and the prevention of CMV disease has not been identified. Currently available antiretroviral therapies are hampered by both significant toxicities and the development of resistance. In addition, agents for preventing CMV disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased compliance secondary to toxicities. Moreover, discordant results have been reported regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need for newer agents with anti-HIV and anti-herpesvirus activity that have good pharmacokinetic and safety profiles and that will be well tolerated by patients. Adefovir dipivoxil is an oral pro-drug of PMEA, a nucleoside analog with activity against a broad spectrum of retroviruses and herpesviruses, including important human pathogens, such as HIV-1, HIV-2 and CMV. Due to its anti-HIV and anti-herpesvirus activity, adefovir dipivoxil may be able to decrease the incidence of opportunistic herpesvirus infections and prolong survival in patients with advanced HIV infection. All patients will be enrolled within the first 18 months of the study. They will be randomized to 1 of 2 groups. Group 1 will be comprised of 1080 patients and will receive adefovir dipivoxil plus L-carnitine and group 2 will be comprised of 1080 patients and will receive a placebo plus L-carnitine. At least the first 400 patients enrolled (200 in each group) will comprise the safety-HIV virology cohort. These patients will have more frequent follow up visits, additional laboratory evaluations, and more intensive safety data information during the first 6 months. NOTE: At least 850 patients who are infected with CMV are followed for the development of CMV end-organ disease in a CMV prophylaxis substudy. AS PER AMENDMENT 8/7/97: All patients are enrolled in the primary study and randomized to the treatment or placebo regimen. Within the primary study, patients meeting specified criteria may be enrolled in one or more of the following cohorts: 1. Safety-HIV virology cohort (at least the first 400 patients enrolled in the study regardless of CMV status). 2. CMV bDNA cohort (those patients in the safety-HIV virology cohort who are CMV-positive). 3. CMV-virology cohort (the first 400 patients in the CMV bDNA cohort enrolled at sites able to obtain CMV urine cultures). All patients who are CMV-positive are enrolled in the CMV prophylaxis substudy.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Chronically administered concomitant therapies for HIV and opportunistic diseases, including chemotherapy for cutaneous Kaposi's sarcoma, must be on these therapies for at least 30 days prior to study entry. - Short courses of oral antibiotics or other therapies given for a limited period of 3 weeks. - Episodic use of IV acyclovir or oral acyclovir > 1g/day for treatment of acute illness is permitted at the clinician's discretion. Patients must have: - A working diagnosis of HIV infection based on the patient's medical history, behavioral history, clinical signs and symptoms, or results of other laboratory tests. - CD4+ cell count <= 100 cells/mm3 within 60 days prior to randomization (OR, AS PER AMENDMENT 8/7/97, a CD4+ cell count that is both > 100 and <= 200 cells/mm3 within 60 days prior to randomization and a documented nadir CD4+ cell count <= 50 cells/ mm3 at any time prior to randomization). - Reasonably good health. - Life expectancy of at least 6 months. - Access to a refrigerator for the storage of adefovir dipivoxil. - Signed informed consent from parent or legal guardian for patients less than 18 years of age. AS PER AMENDMENT 8/7/97: - CMV serology (IgG) positive (CMV bDNA cohort and CMV-virology cohort). Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Evidence of active CMV disease at screening. - Conditions that would require use of medications listed in Exclusion Concurrent Medications. Concurrent Medication: Excluded: - Any investigational anti-CMV agent. - Adenine arabinoside (vidarabine). - Amantadine hydrochloride (Symmetrel). - Cidofovir (Vistide). - CMV hyperimmune globulin. - Cytosine arabinoside (cytarabine). - Famciclovir. - Foscarnet (phosphonoformic acid). - Ganciclovir (Cytovene). - GW 1263W94 (Benzamidazole). - Idoxuridine. - Intravenous acyclovir. - ISIS 2922 (Anti-sense). - Lobucavir. - MSL109. - Oral acyclovir > 1 g/day. - Valacyclovir. Patients with the following prior conditions are excluded: - History of CMV end-organ disease. Prior Medication: Excluded within 2 weeks of randomization: - Any investigational anti-CMV agent. - Adenine arabinoside (vidarabine). - Amantadine hydrochloride (Symmetrel). - Cidofovir (Vistide). - CMV hyperimmune globulin. - Cytosine arabinoside (cytarabine). - Famciclovir. - Ganciclovir (Cytovene). - GW 1263W94 (Benzamidazole). - Idoxuridine. - Intravenous acyclovir. - ISIS 2922 (Anti-sense). - Lobucavir. - MSL109. - Oral acyclovir > 1 g/day. - Valacyclovir. Excluded within 60 days prior to study entry: - Foscarnet.
Total Enrollment: 500
Location and Contact Information:
Overall Study Official:
BrosgartC, Study Chair,
North Jersey Community Research Initiative
Newark, New Jersey, 071032842
United States
AIDS Research Alliance - Chicago
Chicago, Illinois, 60657
United States
Wayne State Univ - WSU/DMC / Univ Hlth Ctr
Detroit, Michigan, 48201
United States
The Research and Education Group
Portland, Oregon, 97210
United States
Community Consortium / UCSF
San Francisco, California, 94110
United States
Partners in Research / New Mexico
Albuquerque, New Mexico, 87131
United States
Richmond AIDS Consortium / Div of Infect Diseases
Richmond, Virginia, 232980049
United States
Henry Ford Hosp
Detroit, Michigan, 48202
United States
Washington Reg AIDS Prog / Dept of Infect Dis
Washington D.C., District of Columbia, 20422
United States
Denver CPCRA / Denver Public Hlth
Denver, Colorado, 802044507
United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, 303081962
United States
Philadelphia FIGHT
Philadelphia, Pennsylvania, 19107
United States
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
New Orleans, Louisiana, 70112
United States
Southern New Jersey AIDS Cln Trials / Dept of Med
Camden, New Jersey, 08103
United States
Harlem AIDS Treatment Grp / Harlem Hosp Ctr
New York City, New York, 10037
United States
Additional Information:
Study ID Numbers: CPCRA 039;
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001082
Other Hiv Infections Studies:
1. Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS
2. Zidovudine Levels in HIV Infected Patients Being Treated for HCV
3. A "Pre-Enrollment" Protocol for HIV-Infected Adolescents
4. A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients with PGL and/or Constitutional Disease
5. Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC
Related Studies:
Other HIV Infections Clinical Trials
Other District of Columbia Clinical Trials
Other Washington D.C. Clinical Trials
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
|
|
|
|
|
|
|
|
